Revolution Medicines, Inc. (RVMD)

Revolution Medicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-1,372	-1,131	-600.09	-436.37	-248.71	-187.09
Depreciation & Amortization	9.04	8.65	7.63	6.11	5.04	4.15
Stock-Based Compensation	180.6	118.39	79.2	61.77	31.2	20.72
Other Adjustments	56.88	19.7	-44.57	-18.84	1.56	6.31
Change in Receivables	0.47	-	1.25	3.42	1.26	0.46
Changes in Accounts Payable	34.66	9.54	-6.47	32.47	7.29	2.24
Changes in Accrued Expenses	93.98	112.27	21.99	14.67	1.5	8.72
Changes in Unearned Revenue	-	-	-	-4.46	-14.47	-1.66
Changes in Other Operating Activities	-58.6	-34.98	-16.37	-9.35	-9.06	-1.04
Operating Cash Flow	-1,057	-897.74	-557.44	-350.57	-224.4	-147.18
Capital Expenditures	-14.26	-15.99	-10.31	-7.73	-10.82	-6.53
Purchases of Investments	-1,495	-1,795	-2,137	-1,059	-612.77	-671.34
Proceeds from Sale of Investments	1,812	1,929	1,593	724.05	599.47	535.75
Investing Cash Flow	306.62	118.06	-554.39	-342.6	-24.12	-142.12
Issuance of Common Stock	612.87	377.09	863.71	392.39	301.39	294.6
Repurchase of Common Stock	-	-	-	-4.03	-	-
Net Common Stock Issued (Repurchased)	612.87	377.09	863.71	388.37	301.39	294.6
Other Financing Activities	119.01	244.44	95.71	840.83	0.04	-0.42
Financing Cash Flow	859.39	621.52	959.41	1,229	301.43	294.18
Net Cash Flow	108.55	-158.16	-152.42	536.03	52.92	4.88
Free Cash Flow	-1,072	-913.73	-567.74	-358.3	-235.22	-153.71
FCF Margin	-	-	-	-3094.14%	-664.83%	-522.99%
Free Cash Flow Per Share	-5.55	-4.81	-3.38	-3.17	-2.92	-2.11
Levered Free Cash Flow	-1,307	-1,052	-603.62	-404.65	-269.23	-181.21
Unlevered Free Cash Flow	-1,322	-1,103	-692.19	-451.57	-278.36	-182.12

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q